IDH1 and acute myeloid leukemia: In May 2022, the combination of ivosidenib, an IDH1 inhibitor, and azacitidine was approved by the FDA for older patients with newly diagnosed IDH1-mutated AML.240 Other drugs being combined with HMAs include HDAC inhibitors, polo-like kinase 1 inhibitors, T-cell immunoglobulin domain and mucin domain-3 antibodies, and PD-L1 antibodies.857–860 These combinations are currently under evaluation in ongoing registrational clinical trials across different stages, with promising results anticipated for updating clinical strategies.